Original InvestigationLeft Atrial Appendage Closure Versus Direct Oral Anticoagulants in High-Risk Patients With Atrial Fibrillation
Central Illustration
Key Words
Abbreviations and Acronyms
Cited by (0)
This work was supported by a research grant from the Ministry of Health, Czech Republic (AZV 15-29565A). Dr. Osmancik has received occasional speaking honoraria from Bayer and Abbott. Dr. Taborsky has served on the Advisory Boards for Bayer and Pfizer. Dr. Kala has served on the Speakers Bureau and Advisory Board for Bayer; and has served on the Advisory Board and as a consultant for Boston Scientific. Dr. Poloczek has received speaking honoraria from Abbott. Dr. Haman has received speaking honoraria from Pfizer. Dr. Zemanek has received speaking honoraria from Abbott and Bayer. Dr. Widimsky has received honoraria from Bayer, Pfizer, and Boehringer Ingelheim. Dr. Reddy has received consulting income and grant support from Abbott Inc. and Boston Scientific Inc. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Jacqueline Saw, MD, served as Guest Associate Editor for this paper. Deepak L. Bhatt, MD, MPH, served as Guest Editor-in-Chief for this paper.
The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the JACC author instructions page.
- ∗
Drs. Widimsky and Reddy are co-senior authors.